Merck (MRK) Current Assets (2009 - 2026)
Merck (MRK) posted quarterly Current Assets of $35.0 billion for Q1 2026, down 1.37% year-over-year from $35.5 billion in Q1 2025, and down 19.54% quarter-over-quarter from $43.5 billion in Q4 2025.
Merck (MRK) Current Assets (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Current Assets for 18 consecutive years, with $35.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 1.37% year-over-year to $35.0 billion; the TTM figure through Mar 2026 stood at $35.0 billion (down 1.37% YoY), while the FY2025 annual figure was $43.5 billion, up 12.21% from the prior year.
- Current Assets eased to $35.0 billion in Q1 2026 per MRK's latest filing, from $43.5 billion in the prior quarter.
- Across five years, Current Assets topped out at $47.6 billion in Q3 2025 and bottomed at $30.0 billion in Q2 2023.
- Historically, Current Assets has averaged $35.7 billion across 5 years, with a median of $35.0 billion in 2026.
- Annual changes were most pronounced in 2023 — Current Assets slipped 9.95% — and 2024, when it grew 27.45%.
- Merck's Current Assets stood at $35.7 billion in 2022, then dropped by 9.95% to $32.2 billion in 2023, then rose by 20.56% to $38.8 billion in 2024, then grew by 12.21% to $43.5 billion in 2025, then decreased by 19.54% to $35.0 billion in 2026.
- Business Quant data shows MRK's Current Assets at $35.0 billion in Q1 2026, $43.5 billion in Q4 2025, and $47.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.68 Bn |
| Mar 31, 2026 | 35.02 Bn |
| Dec 31, 2025 | 43.52 Bn |
| Sep 30, 2025 | 47.56 Bn |
| Jun 30, 2025 | 37.07 Bn |
| Mar 31, 2025 | 35.50 Bn |
| Dec 31, 2024 | 38.78 Bn |
| Sep 30, 2024 | 40.36 Bn |
| Jun 30, 2024 | 38.21 Bn |
| Mar 31, 2024 | 31.45 Bn |
| Dec 31, 2023 | 32.17 Bn |
| Sep 30, 2023 | 31.95 Bn |
| Jun 30, 2023 | 29.98 Bn |
| Mar 31, 2023 | 33.40 Bn |
| Dec 31, 2022 | 35.72 Bn |
| Sep 30, 2022 | 33.56 Bn |
| Jun 30, 2022 | 32.12 Bn |
| Mar 31, 2022 | 31.18 Bn |
| Dec 31, 2021 | 30.27 Bn |
| Sep 30, 2021 | 31.06 Bn |